Management of Penicillin and Beta-Lactam Allergy Guidelines*
(Health PEI Provincial Drugs & Therapeutics Antimicrobial Stewardship Subcommittee, October 2017)

*Adapted from New Brunswick Provincial Health Authorities Anti-Infective Stewardship Committee’s February 2016 document Management of Penicillin and Beta-Lactam Allergy. (http://en.horizonnb.ca/home/careers-and-education/learning/antimicrobial-use.aspx)

New Brunswick Acknowledgements:
- Main authors: Tim MacLaggan, Dan Landry, Holly Glennie, Mario Levesque, Jon Stevens
- Members of the NB Health Authorities Anti-Infective Stewardship Committee (NB-ASC)
- Members of the NB Health Authorities Anti-Infective Stewardship Committee Working Group

Key Points

Background:
- Beta-lactams are generally safe; allergic and adverse drug reactions are over-diagnosed and reported
- Nonpruritic, nonurticarial rashes occur in up to 10% of patients receiving penicillins. These rashes are usually not allergic and are not a contraindication to the use of a different beta-lactam
- The frequently cited risk of 8 to 10% cross-reactivity between penicillins and cephalosporins is an overestimate based on studies from the 1970’s that are now considered flawed
- Expect new intolerances (i.e. any allergy or adverse reaction reported in a drug allergy field) to be reported after 0.5 to 4% of all antimicrobial courses depending on the gender and specific antimicrobial. Expect a higher incidence of new intolerances in patients with three or more prior medication intolerances.¹

New Way of Thinking about Cross-Reactivity Between Beta-Lactams:
- For type-1 immediate hypersensitivity reactions (IgE-mediated), cross-reactivity among penicillins (table 1) is expected due to similar core structure and/or major/minor antigenic determinants, use not recommended without desensitization.
- For type-1 immediate hypersensitivity reactions (IgE-mediated), cross-reactivity between penicillins and cephalosporins (table 1) is due to similarities in the side chains; risk of cross-reactivity will only be significant between penicillins and cephalosporins with similar side chains
- Only type-1 immediate hypersensitivity to a penicillin manifesting as anaphylaxis, bronchospasm, angioedema, hypotension, urticaria or pruritic rash warrant the avoidance of cephalosporins with similar side chains and other penicillins
- Patients with type-1 immediate hypersensitivity to a penicillin may be safely given cephalosporins with side chains unrelated to the offending agent (See figure 1 & 2 below)
  - For example, ceFAZolin does not share a side chain with any beta-lactam and is not expected to cross react with other agents
- Cross-reactivity between cephalosporins is low due to the heterogeneity between side chains; therefore, a patient with a cephalosporin allergy may be prescribed another cephalosporin with a dissimilar side chain
- Cross-reactivity between penicillins and carbapenems is low. Carbapenems would be a reasonable option when antibiotics are required in patients with type-1 immediate hypersensitivity reaction to penicillins

Miscellaneous Warnings:
- Patients with reported Stevens-Johnson syndrome or toxic epidermal necrolysis secondary to beta-lactam use should avoid beta-lactams and not receive beta-lactam skin testing, re-challenging or desensitization
- Patients with reported drug reaction with eosinophilia and systemic symptoms (DRESS), immune hepatitis, hemolytic anemia, serum sickness or interstitial nephritis secondary to beta-lactam use should consult the Infectious Diseases Consultant before utilizing any beta-lactam antibiotic.
- Penicillin skin testing has a potential use but is not currently available in PEI. If considering referral to an off-Island immunologist for penicillin skin testing discuss with the Infectious Disease Consultant.

Page 1 of 11
Management of the Beta-Lactam Allergy (Figure 1 & Figure 2) 1,2,3,4

1. Avoid the unnecessary use of antimicrobials, particularly in the setting of viral infections.
2. Complete a thorough investigation of the patient’s allergies, including, but not limited to: the specific drug the patient received, a detailed description of the reaction, temporal relationship of the onset of the reaction with respect to when the drug was given, concomitant drugs received when the reaction occurred, the time elapsed since the reaction occurred and tolerability of any structurally related compounds
   a. Patient reports intolerance (e.g. nausea, vomiting, diarrhea, headache) – likely not allergic, attempt beta-lactam therapy
   b. Patient has a documented severe non-IgE mediated hypersensitivity reaction to a beta-lactam (e.g. severe cutaneous reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), etc…) – avoid all beta-lactam antibiotics including their use for allergy testing, desensitization and re-challenge.
      ▪ Treatment options include non-beta-lactam antibiotics
   c. Patient has a documented severe non-IgE mediated hypersensitivity reaction to a beta-lactam (e.g. interstitial nephritis, immune hepatitis, hemolytic anemia, serum sickness, drug rash with eosinophilia and systemic symptoms (DRESS), etc…) – consult the Medical Microbiologist/Infectious Diseases Consultant.
   d. Patient has a documented severe type-1 immediate hypersensitivity reaction to a penicillin (e.g. anaphylaxis, urticaria, angioedema, hypotension, bronchospasm, stridor, pruritis) – avoid other penicillins and cephalosporins with similar side chain, unless patient undergoes desensitization.
      ▪ Treatment options include cephalosporins with dissimilar side chains or carbapenems or non-beta-lactam antibiotics – Note: ceFAZolin does not share a side chain with any beta-lactam agent.
   e. Patient has a documented severe type-1 immediate hypersensitivity reaction to a cephalosporin (e.g. anaphylaxis, urticaria, angioedema, hypotension, bronchospasm, stridor, pruritis) – avoid cephalosporins with similar side chains and penicillins with similar side chains (see figure 1) unless desensitization is performed.
      ▪ Treatment options include penicillins with dissimilar side chains, cephalosporins with dissimilar side chains, carbapenems or non-beta-lactam antibiotics.
**Figure 1: Beta-Lactam Cross Allergy Matrix (based on similar core and/or side chain structures)**

<table>
<thead>
<tr>
<th>PENICILLINS*</th>
<th>penicillin*</th>
<th>amoxicillin/ampicillin</th>
<th>cloxacillin</th>
<th>piperacillin (pip/tazo)</th>
<th>cefADROxil</th>
<th>cephALEXin</th>
<th>cefCetizol</th>
<th>cefuroxime</th>
<th>cefoxitin</th>
<th>cefTRIAZone</th>
<th>meropenem</th>
<th>ertapenem</th>
</tr>
</thead>
<tbody>
<tr>
<td>penicillin*</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>amoxicillin/ampicillin</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cloxacillin</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>piperacillin (pip/tazo)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1ST GENERATION CEPHALOSPORIN</td>
<td>cefADROxil</td>
<td>*</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cephALEXin</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cefCetizol</td>
<td>*</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2ND GENERATION CEPHALOSPORIN</td>
<td>cefPROzil</td>
<td>*</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cefuroxime</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cefoxitin</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3RD GENERATION CEPHALOSPORIN</td>
<td>cefTAXime</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cefTAXidime</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cefTRIAZone</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CARBAPENEMS</td>
<td>meropenem</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ertapenem</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Each 'X' in the matrix indicates side-chain and/or major/minor antigenic similarity between two antibiotics. For type-1 immediate hypersensitivity including anaphylaxis there is a risk of cross-allergenicity between pairs marked with 'X'. This is due to similar side-chains and/or major/minor antigenic determinants, use NOT recommended without desensitization.

* Caution! Before using cephALEXin, cefADROxil, or cefPROZil in a patient with an allergy to "penicillins" as a group, clarify or confirm the patient is NOT allergic to amoxicillin or ampicillin.

Avoid ALL beta-lactams including beta-lactam skin testing, re-challenge or desensitization in patients with reported Stevens-Johnson syndrome or toxic epidermal necrolysis secondary to beta-lactam use.

Consult Medical Microbiologist / Infectious Diseases Consultant in patients with reported immune hepatitis, drug reaction with eosinophilia and systemic symptoms (DRESS), serum sickness, hemolytic anemia or interstitial nephritis secondary to beta-lactam use.

Carbapenems may be considered with close monitoring in patients with reported allergy to penicillins or cephalosporins since there is little potential for cross-reactivity.
Figure 2: Penicillin Allergy Management Algorithm

Reported Penicillin Allergy

Assess the nature of the allergy

Onset within 1-72 hours of administration of:
- Anaphylaxis, hypotension, bronchoconstriction, allergic rhinitis, early onset urticaria, stridor, angioedema

Further assess the allergy
- How long ago?
- What specific agent?
- Re-challenged?

Intolerance such as:
- Diarrhea, Nausea, Vomiting, Headache

Ok to attempt beta-lactam therapy

Onset after more than 72 hours of administration of:
- non-pruritic morbilliform rash, maculopapular rash

Ok to attempt therapy with a different beta-lactam

Onset after more than 72 hours of administration of:
- immune hepatitis, DRESS, serum sickness, hemolytic anemia or interstitial nephritis

Consult Medical Microbiologist / Infectious Diseases Consultant

Onset after more than 72 hours of administration of:
- Stevens-Johnson syndrome, toxic epidermal necrolysis

Avoid all testing, desensitizing and re-challenging with all beta-lactam antibiotics

Convincing history of an IgE-mediated reaction:
- Avoid all penicillins as well as beta-lactams with a similar side chain (see Beta-Lactam Cross Allergy Matrix) OR consider consult to Medical Microbiologist / Infectious Diseases Consultant to review desensitization/graduated challenge doses vs. selection of a non-beta-lactam antibiotic.
**Therapeutic Review**

Beta-lactam antibiotics are the most commonly prescribed class of antimicrobials and include penicillins, cephalosporins, carbapenems and monobactams (table 1).\(^9\) Due to similarities in their beta-lactam ring structure it has been widely accepted that penicillins, cephalosporins and carbapenems have significant cross-reactivity with other classes of beta-lactams.\(^5,8,10,11\) Historically it has been reported that approximately 10% of patients allergic to penicillins are also allergic to cephalosporins and up to 50% cross-reactivity has been reported between penicillins and carbapenems.\(^4,5,9,10,11\) Therefore, it has been commonly recommended that patients with a severe allergic reaction to one class of beta-lactam antibiotic should not receive any beta-lactam antibiotic.\(^9\) This historic over-estimation of cross-sensitivity between classes of beta-lactams is inaccurate and based on flawed methodologies.\(^12\)

Studies have shown that physicians are more likely to prescribe antimicrobials from other classes when patients have a documented penicillin or cephalosporin allergy.\(^13,14\) Non beta-lactam alternatives may be: less effective, more toxic, broader spectrum, more expensive and more likely to lead to infection or colonization with resistant organisms.\(^4,13,15,16,17\) The inaccurate documentation of a penicillin allergy can lead to undesirable patient outcomes. For example, one study showed that patients with a documented penicillin allergy at admission spend more time in hospital and are more likely to be exposed to antibiotics associated with *C. difficile* and vancomycin resistant *Enterococcus*.\(^18\) In addition they had increased prevalence rates for infections secondary to *C. difficile*, vancomycin-resistant *Enterococcus* and methicillin-resistant *Staphylococcus aureus*.\(^18\)

Practice however is changing because allergies have been better defined and the role of the chemical structure on the likelihood of cross-reactivity is now better understood. Recent data shows that the rate of allergic cross-reactivity between penicillins and other beta-lactams is much lower than previous estimates.\(^4,5,9,11\)

Determining the nature of the patient’s reaction is an important step in differentiating between an allergic reaction and an adverse drug reaction such as nausea, vomiting, diarrhea and headache.\(^5,9\) Immunologic reactions to medications are generally classified according to the Coombs and Gell classification of hypersensitivity reactions (see table 2).\(^5,9\) The onset and presentation of the reaction can be used to help classify the reaction and determine whether or not a beta-lactam antibiotic may be used (table 2).\(^5,9\) Type-1, immediate hypersensitivity reactions, are immunoglobulin (Ig) E-mediated reactions and are the only true allergic reactions where the potential risk of cross-reactivity between beta-lactams should be considered.\(^5,9\) Type-1 immediate hypersensitivity reactions usually occur within 1 hour of exposure and typically manifest as anaphylaxis, bronchospasm, angioedema, stridor, wheezing, hypotension, urticaria or a pruritic rash.\(^5\) The incidence of these reactions is very low.\(^19\) Nonurticarial and nonpruritic rashes are almost certainly not IgE-mediated.\(^5\)

**Penicillins**

Penicillin is the most frequently reported drug allergy and is reported in 5-10% of the population.\(^20,21,22\) Studies have shown that between 80 and 95% or more of those patients reporting a penicillin allergy do not in fact have true hypersensitivity reactions and the vast majority of these patients can tolerate beta-lactams.\(^1,10,21,22,23,24,25\)
The use of penicillins can be associated with a nonimmediate, nonpruritic, nonurticarial rash in up to 10% of patients that is unlikely to be IgE-mediated and most often idiopathic or T-cell mediated.\textsuperscript{5,26} While inconvenient, these reactions have not been associated with anaphylaxis and pose no risk of cross reactivity with other beta-lactams.\textsuperscript{26} An example is the nonpruritic maculopapular rash commonly seen after the administration of ampicillin or amoxicillin to children suffering from infectious mononucleosis secondary to the Epstein-Barr virus.\textsuperscript{27}

Only a type-1 immediate (IgE-mediated) hypersensitivity reaction to a penicillin manifesting as: anaphylaxis, bronchospasm, angioedema, hypotension, urticaria or pruritic rash warrants the avoidance of other penicillins and cephalosporins with similar side chains.\textsuperscript{4,5,9,11} Cross-reactivity between penicillins (figure 1) may be due to shared common antigenic determinants based on similarities in their core ring structure that is common to all penicillins and/or the side chains that distinguish different penicillins from one another; therefore, cross-reactivity cannot be based on side chain similarities alone.

Currently, there is one Health Canada-approved standardized penicillin skin test. PRE-PEN contains the major antigenic determinant of penicillin and is used to rule out a type-1 immediate (IgE-mediated) penicillin allergy. Available literature suggests that the skin test using both major and minor antigenic determinants are roughly 50-60\% predictive of penicillin hypersensitivity with a 97-99\% negative predictive value.\textsuperscript{4} When penicillin skin testing is not available, the approach to penicillin allergic patients is based on their reaction history and the need for treatment with a penicillin.\textsuperscript{28} While patients with a convincing reaction history are more likely to be allergic, those with vague histories cannot be discounted as they may also be penicillin allergic.\textsuperscript{28} The time passed since the reaction is useful because 50-80\% of penicillin allergic patients lose their sensitivity after 5 and 10 years respectively.\textsuperscript{2,29,30}

Skin testing, desensitization or re-challenge with a beta-lactam should not be performed in those patients with a history of Stevens-Johnson syndrome or toxic epidermal necrolysis.\textsuperscript{5} In patients with DRESS, serum sickness, immune hepatitis, hemolytic anemia or interstitial nephritis, it is recommended to consult the Medical Microbiologist/Infectious Diseases Consultant.

**Cephalosporins**

Cephalosporin-induced skin reactions, described as urticaria, rash, exanthema and pruritus, occur in approximately 1 to 3\% of patients.\textsuperscript{31}

Early analysis of cephalosporin use in penicillin allergic patients was complicated by the uncritical evaluation of “allergic reaction”.\textsuperscript{5,9,11} Any adverse reaction to cephalosporins was often classified as “allergic”.\textsuperscript{5,9,11} This, accompanied with possible penicillin contamination in early cephalosporin production, resulted in overestimations of cross sensitivity.\textsuperscript{5,9} In addition, penicillin allergic patients are more likely to have an allergy to any drug when compared to other patients.\textsuperscript{4,5,9,10,11} Investigations have shown that individuals with a penicillin allergy are three times more likely to develop new allergies to unrelated compounds, leading to further overestimations of cross-reactivity.\textsuperscript{5,9,10}

Cross-reactivity between penicillins and cephalosporins is due to similarities in side chains at the C-3 or C-7 position as shown in table 3 and not similarities in beta-lactam ring structure as previously speculated.\textsuperscript{4,5,9,11} The American Academy of Pediatrics states that the likelihood of a penicillin allergic
patient reacting to a cephalosporin with a different side chain is similar to that of a non-penicillin allergic patient. A prospective study with skin test or challenge dose confirmed penicillin allergy demonstrated a 0% cross-reactivity to ceFAZolin, cefuroxime and cefTRIAXone. None of these agents share a side chain with penicillin.32 Meanwhile the risk of cross-reactivity may be up to 40% between penicillins and cephalosporins with the similar R-group side chains.3,33

Cross-reactivity between cephalosporins is low because of the significant heterogeneity of the side chains at the C-3 and C-7 positions.9,34 Therefore, if a patient has a cephalosporin allergy, one can safely prescribe another cephalosporin that has dissimilar side chains at both C-3 and C-7 positions.34

CeFAZolin is not expected to cross react with any penicillin or cephalosporin as it does not share a side chain with any beta-lactam.4,34

Carbapenems

Early studies evaluating the risk of cross-reactivity between penicillin and carbapenems found rates upwards of 47%. However, these studies had poor definitions of allergy and variable methods for determining allergy status.9 A more recent systematic review was completed to collect and combine all published data on pediatric and adult patients reported to have a clinical history of type-1 immediate hypersensitivity (IgE-mediated) to a penicillin and/or cephalosporin who were then given a carbapenem.35 Within the study allergic reactions were classified as proven, suspected or possible IgE-mediated and non-IgE-mediated.35 Overall, for patients with a history of proven, suspected or possible IgE-mediated reaction to a penicillin; 4.3% (36/838) had a suspected hypersensitivity reaction to a carbapenems but only 20 were compatible with an IgE-mediated reaction and only one was considered to be proven.35 The authors concluded that carbapenems would be a reasonable option when antibiotics are required in patients with IgE-mediated reactions to penicillins.35 They advise that clinicians proceed with caution by administering the first dose of carbapenem in a setting where anaphylaxis can be managed and to consider giving via a graduated challenge.35 If at any stage the patient reacts then the options are to use a carbapenem desensitization protocol or switch to a non-beta-lactam antibiotic.35

Desensitization

Desensitization, or temporary induction of drug tolerance, is used for patients with a documented or convincing history of type-1 immediate (IgE-mediated) beta-lactam allergy and/or positive skin test and a serious infection where non-cross-reacting alternatives are not appropriate.2,28 The goal of desensitization is to modify a patient’s immune response to allow safe treatment with the allergenic drug.28

Desensitization will not prevent non-IgE mediated reactions and should never be attempted in patients with reactions involving major organs or severe cutaneous reactions (e.g. interstitial nephritis, SJS, TEN, DRESS, etc.).2

Desensitization is performed by administering incremental doses of the allergenic drug.3 Usually the procedure is complete within hours and starts in the microgram range.28 Dosages are usually doubled
every 15 to 30 minutes until therapeutic doses are achieved.\textsuperscript{28} When the desensitization process is complete, treatment with the select beta-lactam should be started immediately and must not be interrupted during the treatment course.\textsuperscript{2,28} Desensitization is usually lost within two days of cessation and must be repeated if the beta-lactam is required in the future.\textsuperscript{2,28}

**Graduated Challenge**

Graduated challenges are used when there is a low likelihood of drug allergy and differ from desensitization in that they do not alter the patient’s underlying immune response to the drug in question.\textsuperscript{26} Their purpose is to allow cautious administration in patients unlikely to be allergic when there is no intention to alter the patient’s immune response.\textsuperscript{28} If the graduated challenge is tolerated the patient is then considered not to be allergic and not at increased risk for future reactions.\textsuperscript{28} Graduated challenges should never be performed in patients with reactions involving major organs or non-IgE mediated severe cutaneous reactions.\textsuperscript{28}

The starting dose of a graduated challenge is often higher than that used for desensitization and usually only involves 2 to 3 steps and completed within hours.\textsuperscript{28} For a graduated challenge for an intravenous antibiotic, 1\% of the full dose is administered, then 10 \% of the full dose, then the full dose, separated by 30 minutes to 1 hour each and under careful observation.\textsuperscript{2,3} If at any point a reaction occurs the graduated challenge is stopped.

The decision to use a graduated challenge is based on the risk of cross-reactivity and the description and remoteness of the allergic reaction in question. Treatment options requiring desensitization or graduated challenge should be avoided in severe infections (e. g. febrile neutropenia, sepsis, meningitis, etc.) where delays in appropriate drug therapy are associated with poor patient outcome, in these scenarios a non-beta lactam treatment option should be considered for empiric therapy.

**Table 1: Classification of Beta-Lactams**

<table>
<thead>
<tr>
<th>Penicillins</th>
<th>Cephalosporins</th>
<th>Carbapenems</th>
<th>Monobactam</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>First Generation</td>
<td>Second Generation</td>
<td>Third Generation</td>
</tr>
<tr>
<td>penicillin</td>
<td>cefadroxil</td>
<td>cefaclor</td>
<td>ceTAZidime</td>
</tr>
<tr>
<td>ampicillin</td>
<td>ceFAZolin</td>
<td>cefOXitin</td>
<td>cefixime</td>
</tr>
<tr>
<td>amoxicillin</td>
<td>cephalalexin</td>
<td>cefprozil</td>
<td>cefTRIAXone</td>
</tr>
<tr>
<td>cloxacillin</td>
<td></td>
<td>cefuroxime</td>
<td>cefotaxime</td>
</tr>
<tr>
<td>piperacillin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ticarcillin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type</td>
<td>Mediator</td>
<td>Onset</td>
<td>Clinical Reaction</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>---------------------------</td>
<td>------------------------</td>
<td>---------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| I - Immediate and Acute hypersensitivity  | IgE antibodies           | Less than 1hr (Rarely up to 72 hours) | Anaphylaxis, urticaria, angioedema, hypotension, bronchospasm, stridor, pruritis | Anaphylaxis: Penicillins 0.01-0.05%  
Cephalosporins 0.0001-0.1%  
Avoid the offending agent and side chain related agents (See Figure 1) |
| II – Delayed cytotoxic antibody-mediated hypersensitivity | IgG and IgM antibodies | Greater than 72 hours  | Hemolytic anemia, thrombocytopenia, neutropenia                     | Drug specific, avoid the offending agent                                  |
| III – Antibody complex-mediated hypersensitivity | IgG and IgM complexes | Greater than 72 hours  | Serum sickness, glomerulonephritis, small vessel vasculitis, drug fever | Antibody-antigen complexes precipitate in tissues and potentially affect any end organ |
| IV – Delayed type hypersensitivity       | T-Cells                   | Greater than 72 hours  | Contact dermatitis, pustulosis                                      | Incidence is low. E.g. Eosinophilia, bullous exanths, severe exfoliative dermatoses (e.g. SJS/TEN), interstitial nephritis, immune hepatitis and some morbilliform or maculopapular rashes |
| Idiopathic Reactions                     | Unknown                   | Usually greater than 72 hours | Maculopapular or morbilliform rashes                               | 1 – 4% of patients receiving beta-lactams  
Not a contraindication to future use of beta-lactam antibiotics |

*Anaphylaxis: defined as serious hypersensitivity reaction that is rapid in onset and may cause death, typically involving the skin, mucosal tissue or both and either respiratory compromise (e.g. dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow, hypoxemia) or reduced blood pressure or the associated symptoms and signs of end-organ dysfunction.*
Table 3: Beta-Lactam Groups with Similar Side-Chains

<table>
<thead>
<tr>
<th>Similar C-7 Side Chain</th>
<th>Similar C-3 Side Chain</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Cross Reactions between agents within one group is possible)</td>
<td>(Cross reactions between agents within one group is possible)</td>
</tr>
<tr>
<td>Group 1</td>
<td>Group 2</td>
</tr>
<tr>
<td>penicillin</td>
<td>cefOXitin</td>
</tr>
</tbody>
</table>

Note:
- CeFAZolin does not share a side chain with any beta-lactam and is not expected to cross react with other agents.
- Amoxicillin, ampicillin, penicillin, cloxacillin, piperacillin and ticarcillin share common major allergic determinants based on similarities in their core structure and/or side chains; therefore, cross-reactivity cannot be based on side chain similarities alone.

References:

10. Herbert ME, Brewster GS, Lanctot-Herbert M. Medical Myth: Ten percent of patients who are allergic to penicillin will have serious reactions if exposed to cephalosporins. West J Med 2000;172:341
27. Aronson MD and Awwaerter PG. Up-to-Date Infectious mononucleosis in adults and adoleants. In. Accessed online August 2015
35. Kula B, Djordjevic G, and Robinson JL. A Systematic Review: Can one Prescribe Carbapenems to Patients with IgE-Mediated Allergy to Penicillins or Cephalosporins? CID 2014;59(8):1113-1122